IP Library Granted Patent US 9,511,108
Granted Patent B2
US 9,511,108 · App. 14/491,785 · Granted Dec 6, 2016

Pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases, containing

Inventors: Jinju Kim (Gwacheon-si, KR); Eunjung Ko (Seoul, KR); Eui Jeong Lee (Seoul, KR)
Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
A61K36/899A23L33/105A61K36/074A61K36/804
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,108
App. No.
14/491,785
Granted
Dec 6, 2016
Kind
B2
Abstract

The present invention relates to a method for treating chronic obstructive pulmonary disease (COPD) comprising the step of administering the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. Particularly, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention can reduce the numbers of macrophages and neutrophils increased in bronchoalveolar lavage fluid (BALF) and is effective in preventing weight loss caused by chronic obstructive pulmonary disease and is effective in down-regulating significantly IL-6, TNF-α, IL-1β, MCP-1, and MMP-12, which are rapidly increased in bronchoalveolar lavage fluid, intrapulmonary tissue, and serum according to the development of chronic obstructive pulmonary disease. In addition, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention has the effect of blocking the activation of NF-κB signal in intrapulmonary tissue and significantly reduces inflammatory cells in the tissues around alveoli as well as significantly reduces the size of the enlarged alveola. Therefore, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention can be effectively used as an active ingredient of medicines and health food for the prevention and treatment of chronic obstructive pulmonary disease.

Claims (18)

1. A method for treating a subject with emphysema, comprising administering an effective amount of an extract of Phyllostachys nigra Munro var. henosis Stapf to a subject in need thereof, thereby treating the emphysema.

2. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf is extracted by using water, alcohol, or the mixed solvent thereof as an extraction solvent.

3. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf is prepared by the following steps:

1) adding an extraction solvent to Phyllostachys nigra Munro var. henosis Stapf, followed by extraction;

2) filtering the extract obtained in step 1); and

3) concentrating the extract filtered in step 2) under reduced pressure and drying thereof.

4. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf is prepared by the following steps:

1) adding distilled water to Phyllostachys nigra Munro var. henosis Stapf, followed by reflux-extraction;

2) filtering the extract obtained in step 1) with a filter; and

3) concentrating the extract filtered in step 2) under reduced pressure and freeze-drying thereof.

5. The method for treating the subject with emphysema according to claim 1 , wherein the emphysema is caused by smoking.

6. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf reduces the populations of macrophages and neutrophils in bronchoalveolar lavage fluid (BALF).

7. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf suppresses weight loss.

8. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf reduces the levels of IL-6, TNF-α, and IL-1β in BALF, pulmonary parenchymal tissue or serum.

9. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf characteristically reduces the levels of MCP-1 and MMP-12 in BALF, pulmonary parenchymal tissue or serum.

10. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf blocks the activation of NF-κB signal in pulmonary parenchymal tissue.

11. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf reduces the number of inflammatory cells around alveola.

12. The method for treating the subject with emphysema according to claim 1 , wherein the extract of Phyllostachys nigra Munro var. henosis Stapf reduces the size of alveola.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2014
From: KIM, JINJU; KO, EUNJUNG; LEE, EUI JEONG
To: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
Reel/Frame 033842/0361 →
Priority Claims (1)
KR 10-2012-0029398 · Mar 22, 2012 · national
Continuity (2)
Continuation In Part PCTKR2013001802 · Mar 6, 2013
Related Publication 20150037441A1 · Feb 5, 2015